MedTrace Logo

To Evaluate the Safety and Pharmacokinetic Interaction Between HODO-22251 and HODO-22252 in Healthy Adults

NCT06578676 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2024-08-29

No results posted yet for this study

Summary

The purpose of this study is to evaluate pharmacokinetic interaction and safety of co-administrated 25mg of Empagliflozin and 10/10mg Ezetimibe/Rosuvastatin in steady state in healthy volunteers.

Conditions

Interventions

DRUG

Empagliflozin 25 MG

PO, QD

DRUG

Ezetimibe/Rosuvastatin 10/10mg

PO, QD

DRUG

Empagliflozin 25 MG with Ezetimibe/Rosuvastatin 10/10mg

PO, QD

Sponsors & Collaborators

  • Kyungpook National University Hospital

    collaborator OTHER

  • Hyundai Pharm

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-06-20
Primary Completion
2024-09-02
Completion
2024-11-30

Countries

  • South Korea

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06578676 on ClinicalTrials.gov